Cargando…

A targeted approach to reducing rates of discontinuation and dose reduction in patients receiving sorafenib or regorafenib

Background: Sorafenib and regorafenib are oral multikinase inhibitors used to treat some cancers, but adverse events for both drugs are common and often cause patients to discontinue therapy or reduce their dose within several months of initiating therapy. Pharmacists have the potential to prevent d...

Descripción completa

Detalles Bibliográficos
Autores principales: Nix, Ryan, Looney, Brooke, Lamb, Carson, Peter, Megan, Zuckerman, Autumn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764342/
http://dx.doi.org/10.1080/21556660.2019.1658310